Contact
Search
Our Company
Leadership Team
Careers
Grants & Sponsorships
Expanded Access
Contact Us
Programs & Pipeline
Programs
Pipeline
Resources
For Patients & Providers
Mitochondria & Disease
Mitochondrial Diseases
Community
Contact Us
Scientific Data
Publications
Presentations
Investors & News
About
Stock Information
Reports & Filings
News
Publications
IR Presentations
Events
Corporate Governance
Contact Us
Reports
Email Alerts
Contact Us
Investors & News
Latest News
Feb 23,2021
Stealth BioTherapeutics Completes Enrollment of Phase 2 Study in Dry Age-Related Macular Degeneration with Geographic Atrophy
Feb 10,2021
Stealth BioTherapeutics Announces Pricing Of $4.7 Million Registered Direct Offering Of American Depositary Shares
Jan 07,2021
Stealth BioTherapeutics to Participate in Upcoming January Investor Conferences
All News
Stock Quote (MITO)
Share
Why invest?
Our Company
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.
Our Programs
We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.
Our Pipeline
We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.
Latest Reports
February 26, 2021
Form S-8 : Securities Registration: Employee Benefit Plan
HTML
February 17, 2021
Form SC 13D/A : Amended Statement of Beneficial Ownership
HTML
Reports
Latest Presentations
January 28, 2021
Investor Presentation February 2021
February 18, 2020
Barth Syndrome Efficacy Study Using Natural History Data as a Control
Presentations
Events
January 11, 2021
H.C. Wainwright Virtual BioConnect Conference at 6:00 am ET
Webcast
January 11, 2021
Stern Investor Relations Corporate Access Event at 7:00am ET
Webcast
Financial Calendar
Media Relations
Amelia Stetler, 617-762-2562
media@stealthbt.com
Investor Inquiries
Stern IR
Janhavi Mohite, 212-362-1200
IR@stealthbt.com
